TIDMRTW
RNS Number : 8822P
RTW Venture Fund Limited
22 October 2021
LEI: 549300Q7EXQQH6KF7Z84
22 October 2021
RTW Venture Fund Limited
Portfolio Company Update: Ventyx IPO
Ventyx Prices Upsized $151.5 Million IPO
RTW Venture Fund Limited (the "Company"), a London Stock
Exchange-listed investment company focused on identifying
transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors, is pleased to
note the 20 October 2021 a nnouncement by one of its portfolio
companies, Ventyx Biosciences , Inc. ("Ventyx") regarding its
pricing of an upsized $151.5 million initial public offering
("IPO") and admission to trade on Nasdaq Global Market under ticker
"VTYX".
Ventyx is a clinical-stage biopharmaceutical company advancing a
pipeline of novel small molecule therapeutics with a best-in-class
potential for patients with inflammatory and autoimmune diseases.
Ventyx's pipeline programs include: (1) a selective allosteric TYK2
inhibitor for a broad range of immunological disorders, (2) a
tissue selective S1P1R modulator for inflammatory bowel disease
(IBD), and (3) a preclinical NLRP3 inhibitor program.
Prior to IPO, the Company, together with other funds managed by
RTW Investments, LP (the "Investment Manager"), participated in
Ventyx's $114 million financing round in March 2021.
Ventyx's IPO raised $151.5 million by offering c. 9.5 million
shares at $16.00 per share. On the first day of trading, Ventyx's
share price increased by 31.4% to close at $21.02 per share.
Stephanie Sirota, Chief Business Officer of the Investment
Manager and Director of the Company, said:
"We are excited about Ventyx's successful IPO and look forward
to supporting the company in its efforts to develop innovative
therapeutics for patients with inflammatory and autoimmune
diseases".
Ventyx's IPO pricing announcement can be accessed on its website
at: www.ventyxbio.com, the full text of which is contained
below.
For Further Information
RTW Investments, LP +1 (646) 343 9280
Stephanie Sirota, Chief Business Officer
Alexandra Taracanova, PhD, Director of Investor Relations
Julia Enright, Senior Business Development Associate
Buchanan +44 (0)20 7466 5107
Charles Ryland
Henry Wilson
George Beale
About RTW Venture Fund Limited:
RTW Venture Fund Limited (LSE: RTW) is an investment company
focused on identifying transformative assets with high growth
potential across the biopharmaceutical and medical technology
sectors. Driven by a long-term approach to support innovative
businesses, RTW Venture Fund Limited invests in companies
developing next-generation therapies and technologies that can
significantly improve patients' lives.
RTW Venture Fund Limited is managed by RTW Investments, LP, a
leading healthcare-focused entrepreneurial investment firm with
deep scientific expertise and a strong track record of supporting
companies developing life-changing therapies.
Visit the RTW website at www.rtwfunds.com for more
information.
Ventyx Biosciences Announces Pricing of Upsized Initial Public
Offering
ENCINITAS, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Ventyx
Biosciences, Inc. ("Ventyx"), a clinical-stage biopharmaceutical
company focused on advancing new therapies for millions of patients
living with inflammatory diseases and autoimmune disorders, today
announced the pricing of its upsized initial public offering of
9,472,656 shares of its common stock at a public offering price of
$16.00 per share. All of the shares are being offered by Ventyx. In
addition, Ventyx has granted the underwriters a 30-day option to
purchase up to an additional 1,420,898 shares of common stock at
the initial public offering price, less the underwriting discounts
and commissions. The gross proceeds from the offering, before
deducting underwriting discounts and commissions and other offering
expenses payable by Ventyx, are expected to be approximately $151.5
million, excluding any exercise of the underwriters' option to
purchase additional shares. The shares are expected to begin
trading on the Nasdaq Global Select Market on October 21, 2021
under the ticker symbol "VTYX." The offering is expected to close
on October 25, 2021, subject to the satisfaction of customary
closing conditions.
Jefferies, Evercore ISI and Piper Sandler are acting as joint
book-running managers for the offering. LifeSci Capital is also
acting as an underwriter for the offering. A registration statement
relating to these securities became effective on October 20, 2021.
The offering is made only by means of a prospectus, copies of which
may be obtained from: Jefferies LLC, Attention: Equity Syndicate
Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY
10022, by telephone at (877) 821-7388, or by email at
Prospectus_Department@Jefferies.com; Evercore Group L.L.C.,
Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor,
New York, NY 10055, by telephone at (888) 474-0200, or by email at
ecm.prospectus@evercore.com; and Piper Sandler & Co.,
Attention: Prospectus Department, 800 Nicollet Mall, J12S03,
Minneapolis, MN 55402, by telephone at (800) 747-3924, or by email
at prospectus@psc.com .
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Ventyx Biosciences
Ventyx Biosciences is a clinical-stage biopharmaceutical company
focused on advancing new therapies for millions of patients living
with inflammatory diseases and autoimmune disorders. Ventyx's
clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2
inhibitor for the treatment of a broad range of autoimmune
diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the
treatment of ulcerative colitis, and VTX2735, a Phase 1 peripheral
inhibitor of the NLRP3 inflammasome, which is a mediator of
multiple inflammatory conditions. Ventyx is headquartered in
Encinitas, California. For more information about Ventyx, please
visit www.ventyxbio.com .
Investor Relations Contact
Patti Bank Managing Director
Westwicke Partners
(415) 513-1284
IR@ventyxbio.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
PFUDGBDGBXDDGBB
(END) Dow Jones Newswires
October 22, 2021 02:00 ET (06:00 GMT)
Rtw Biotech Opportunities (LSE:RTWG)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Rtw Biotech Opportunities (LSE:RTWG)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024